Belfrage; Anna Karin Gertrud Linea
Patent Applications and Registrations
Patent applications and USPTO patent grants for Belfrage; Anna Karin Gertrud Linea.The latest application filed is for "macrocyclic inhibitors of hepatitis c virus".
- Belfrage; Anna Karin Gertrud Linea - Uppsala SE
| Patent | Date |
|---|---|
| Macrocyclic inhibitors of hepatitis C virus Grant 9,353,103 - Simmen , et al. May 31, 2 | 2016-05-31 |
| Macrocyclic Inhibitors Of Hepatitis C Virus App 20150218153 - Simmen; Kenneth Alan ; et al. | 2015-08-06 |
| Macrocyclic Inhibitors Of Hepatitis C Virus App 20140255347 - Simmen; Kenneth Alan ; et al. | 2014-09-11 |
| Macrocyclic inhibitors of hepatitis C virus Grant 8,754,106 - Simmen , et al. June 17, 2 | 2014-06-17 |
| Macrocyclic Inhibitors Of Hepatitis C Virus App 20130217725 - Simmen; Kenneth Alan ; et al. | 2013-08-22 |
| Macrocyclic Inhibitors Of Hepatitis C Virus App 20130089520 - Simmen; Kenneth Alan ; et al. | 2013-04-11 |
| Macrocylic inhibitors of hepatitis C virus Grant 8,349,869 - Simmen , et al. January 8, 2 | 2013-01-08 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 